Overview

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

Status:
Completed
Trial end date:
2016-05-19
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo in participants with Lennox-Gastaut syndrome (LGS).
Phase:
Phase 3
Details
Lead Sponsor:
GW Research Ltd
Treatments:
Cannabidiol